Objectives: To assess oritavancin activity in vitro against clinically relevant Gram-positive pathogens causing skin and soft-tissue infections (SSTIs) in European and US hospitals.
Introduction
Skin and soft-tissue infections (SSTIs) are often caused by aerobic Gram-positive cocci, including Staphylococcus aureus and b-haemolytic streptococci. 1 In the past decade, new strains of MRSA (especially USA300, ST8) have emerged as an important cause of community-associated (CA) SSTIs in many areas of North America, Europe and other parts of the world. 2 MRSA isolates were shown to be responsible for as many as 60% (98% of MRSA isolates are USA300-like) of the acute purulent SSTI in US emergency departments. 3, 4 In contrast, the epidemiology of SSTIs in European countries differs from that of the USA and is represented by a more heterogeneous S. aureus population. 5 Although USA300-like isolates have been detected in some European countries, isolates associated with MLST-80 are often responsible for CA-MRSA. 6 -8 Complicated SSTIs typically involve deep soft tissue and occur in patients with underlying disease, often requiring surgical intervention, intravenous antibiotic therapy or both. 1 The high incidence of CA-MRSA causing SSTI has complicated the management of such infections and the selection of empirical therapy. 9 -11 These CA-MRSA isolates are usually susceptible to other agents such as clindamycin, doxycycline and trimethoprim/ sulfamethoxazole, which have been considered as therapeutic options for uncomplicated SSTIs. 3 However, although still rare, resistance phenotypes to these drugs have been reported. 12, 13 In addition, as the MRSA epidemiology continues to evolve, it has also become more complex, since both CA and hospital-associated MRSA clones currently circulate in the community and nosocomial settings, providing further difficulties for the management of MRSA infections. 15 Moreover, oritavancin is under regulatory review by EMA for the treatment of patients with acute SSTI. The FDA and EMA regulatory reviews are based on two multicentre clinical trials (SOLO I and II), which enrolled a total of 1959 patients to assess the efficacy and safety of a single dose of oritavancin compared with 7 -10 days of twicedaily doses of vancomycin for the treatment of acute bacterial SSTI suspected or caused by susceptible Gram-positive bacteria, including MRSA. 16, 17 The data presented here assessed the in vitro activity of oritavancin when tested against 13262 clinically relevant Gram-positive pathogens causing SSTIs in European and US hospitals during a four-year longitudinal, multicentre, surveillance programme for oritavancin.
Materials and methods

Clinical isolates
A total of 13 262 clinical isolates deemed to be the primary organism responsible for clinical SSTIs, as per local guidelines, were included in the study (Table 1 ). All participating sites were instructed to only include consecutive and unique isolates (one per patient) until they reached a target number of pathogens predetermined in the study protocol. Isolates were collected during 2010 -13 from 35 sites in Europe (Belgium, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Russia, Spain, Sweden, Turkey, the UK and Ukraine), one in Israel and 27 institutions in the USA. These pathogens were submitted to the coordinating monitoring laboratory (JMI Laboratories, North Liberty, IA, USA), where bacterial identifications for staphylococcal and enterococcal isolates were confirmed by standard algorithms and Vitek w 2 (bioMérieux, Hazelwood, MO, USA) or MALDI-TOF-MS (Bruker Daltonics, Bremen, Germany). All streptococcal isolates were subjected to MALDI-TOF identification.
Antimicrobial susceptibility testing
Isolates were tested for susceptibility by broth microdilution following the CLSI M07-A9 document. 18 The MICs of oritavancin were determined using dry-form panels manufactured by ThermoFisher Scientific (Cleveland, OH, USA). These panels provide results equivalent to the frozen-form broth microdilution panels supplemented with 0.002% polysorbate-80 approved by CLSI. 19 Comparator agents were tested using previously validated dry-form panels manufactured by ThermoFisher Scientific. Quality assurance was performed by concurrent testing of CLSI-recommended (M100-S24, 2014) strains: Enterococcus faecalis ATCC 29212, S. aureus ATCC 29213 and Streptococcus pneumoniae ATCC 49619. 19 FDA-approved interpretive breakpoint criteria were utilized for oritavancin. 15 These interpretive breakpoints are as follows: S. aureus and E. faecalis (vancomycin-susceptible only) at ≤0.12 mg/L; Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus anginosus group at ≤0.25 mg/L. MIC interpretations for comparator agents were based on the EUCAST (2014) breakpoint criteria. 20 Results and discussion (Table 2) . When the oritavancin MICs were plotted against those of vancomycin, the oritavancin modal MIC increased with increasing vancomycin MICs for isolates from both Europe (oritavancin modal MIC range, 0.03 -0.06 mg/L) and the USA (oritavancin modal MIC range, 0.015-0.06 mg/L; Figure 1 ).
CoNS isolates from the USA (MIC 50 , 0.015 mg/L) demonstrated an MIC 50 of oritavancin that was slightly lower than that for isolates from European countries and Israel (MIC 50 , 0.03 mg/L; Tables 1 and 2 ). In contrast, Staphylococcus epidermidis isolates from the USA (MIC 50 /MIC 90 , 0.06/0.12 mg/L) had MIC 50 s and MIC 90 s of oritavancin that were 2-fold higher than those noted for isolates from Europe (MIC 50 /MIC 90 , 0.03/0.06 mg/L), although oritavancin showed an MIC 100 of 0.12 mg/L when tested against both collections. A total of 63.4% and 70.7% of CoNS from Europe and the USA were oxacillin resistant, respectively (Table 2) . Overall, vancomycin, daptomycin and linezolid demonstrated activity in vitro against CoNS, while other comparators had limited coverage (29.3% -87.8% susceptible); these results were similar for both European and US collections of organisms.
Oritavancin (MIC 50 /MIC 90 , 0.015/0.06 mg/L) was equally active when tested against E. faecalis from Europe and the USA, inhibiting 95.6% -99.3% of strains at the FDA breakpoint for susceptibility (≤0.12 mg/L for vancomycin-susceptible E. faecalis) or all isolates at ≤0.5 mg/L, including vancomycin-resistant (VanAphenotype; Tables 1 and 2 ). E. faecalis isolates from both regions were very susceptible (94.9% -100.0% susceptible) to ampicillin, vancomycin, teicoplanin and linezolid ( were the most active tested agents against S. agalactiae (Table 2) . Other agents, such as vancomycin, teicoplanin, daptomycin, linezolid, levofloxacin, tetracycline and trimethoprim/sulfamethoxazole, demonstrated antimicrobial coverage (≥92.5% susceptible) against S. pyogenes and S. agalactiae (Table 2 ). In addition, clindamycin (97.4% and 95.1% susceptible for European and US isolates, respectively) was active against S. pyogenes (Table 2 ). When tested against S. dysgalactiae, oritavancin, penicillin, daptomycin and clindamycin were the most active agents; other comparators demonstrated acceptable (.90%) susceptibility rates, except for erythromycin and tetracycline (Table 2) .
This study evaluated the activity in vitro of oritavancin and comparators against a recent collection of Gram-positive clinical isolates implicated in SSTIs, including MRSA. Overall, the activity of oritavancin was greater than that of the tested comparators, except against S. dysgalactiae isolates, for which comparable activity was noted for oritavancin, penicillin and daptomycin. Although oritavancin in vitro activity against S. aureus decreased as the vancomycin MICs increased (Figure 1) , oritavancin inhibited 98.8% of isolates at the FDA-approved breakpoint (≤0.12 mg/L). These results corroborate those previously published against a large collection of S. aureus collected from blood in the USA and Europe. 21 Equivalent potency results were observed for oritavancin when tested against isolates from Europe and the USA, with marginal differences for CoNS (S. epidermidis) and vancomycin-resistant E. faecium. The data presented here provide baseline in vitro results for oritavancin, which represents a newer addition to the anti-Gram-positive armamentarium. Oritavancin against Gram-positive pathogens
